Monopar Therapeutics Reports Increased Net Losses and Rising R&D Expenses in Q2 2026

Monopar Therapeutics Inc. reported a net loss of $5.3 million for the three months ended June 30, 2026, compared to a loss of $2.5 million for the same period in 2025. For the six months ended June 30, 2026, the company recorded a net loss of $9.2 million, up from a loss of $5.1 million in the prior year. The increase in losses is attributed to a significant rise in research and development (R&D) expenses, which totaled $4.8 million for the second quarter of 2026, compared to $1.7 million in the same quarter of 2025. This increase was primarily driven by higher contractor and consulting expenses, as well as personnel costs related to ongoing clinical trials and product development.

Total operating expenses for the second quarter of 2026 reached $6.6 million, a 103% increase from $3.2 million in the same quarter of 2025. The company’s general and administrative (G&A) expenses also rose, amounting to $1.9 million in the second quarter of 2026, compared to $1.5 million in the previous year. The increase in G&A expenses was largely due to higher personnel costs and consulting fees. Despite these losses, Monopar's interest income increased to $1.3 million in the second quarter of 2026, up from $780,000 in the same period last year, reflecting higher cash balances and interest rates on investments.

In terms of strategic developments, Monopar is focused on advancing its clinical programs, particularly the ALXN1840 investigational drug for Wilson disease, which has received Orphan Drug Designation and Fast Track designation from the FDA. Following the termination of the ALXN1840 program by Alexion Pharmaceuticals, Monopar acquired the rights to the drug in October 2024 and is now responsible for its further development and commercialization. The company has initiated a rolling submission of its New Drug Application (NDA) for ALXN1840, with expectations to complete the submission in the coming months.

As of June 30, 2026, Monopar reported total assets of $135 million, a decrease from $140.7 million at the end of 2025. The company’s cash and cash equivalents stood at approximately $52.8 million, down from $61.8 million at the end of the previous fiscal year. Monopar's accumulated deficit has grown to $98.7 million, reflecting its ongoing investment in R&D and operational activities. The company anticipates that its current cash reserves will be sufficient to fund operations through at least December 31, 2027, as it continues to pursue its clinical development programs and seeks additional funding sources.

Looking ahead, Monopar plans to expand its drug development pipeline and is actively exploring opportunities for in-licensing and acquiring additional product candidates. The company aims to leverage its scientific and clinical expertise to reduce risks and accelerate the development of its therapeutic candidates. However, it acknowledges the uncertainties and challenges associated with clinical trials, regulatory approvals, and the need for substantial additional funding to support its ongoing operations and development efforts.